AZITHROMYCIN powder, for suspension United States - English - NLM (National Library of Medicine)

azithromycin powder, for suspension

dispensing solutions, inc. - azithromycin (unii: f94ow58y8v) (azithromycin - unii:f94ow58y8v) - azithromycin 1 g - azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. non-gonococcal urethritis and cervicitis due to chlamydia trachomatis . azithromycin at the recommended dose, should not be relied upon to treat gonorrhea or syphilis. antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating gonorrhea or syphilis. all patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. therapy with azithromycin may be in

AZITHROMYCIN powder, for suspension United States - English - NLM (National Library of Medicine)

azithromycin powder, for suspension

physicians total care, inc. - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 1 g - azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. non-gonococcal urethritis and cervicitis due to chlamydia trachomatis . azithromycin at the recommended dose, should not be relied upon to treat gonorrhea or syphilis. antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating gonorrhea or syphilis. all patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. therapy with azithromycin may be in

AZITHROMYCIN powder, for suspension United States - English - NLM (National Library of Medicine)

azithromycin powder, for suspension

preferred pharmaceuticals, inc. - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 1 g - azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. non-gonococcal urethritis and cervicitis due to chlamydia trachomatis. prophylaxis of disseminated mycobacterium avium complex (mac) disease azithromycin, taken alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated mac disease in persons with advanced hiv infection [see dosage and administration (2)]. treatment of disseminated mac disease azithromycin, taken in combination with ethambutol, is indicated for the treatment of disseminated mac infections in persons with advanced hiv infection [see use in specific populations (8.4) and clinical studies (14.1)]. to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infection

AZITHROMYCIN tablet, film coated United States - English - NLM (National Library of Medicine)

azithromycin tablet, film coated

rxchange co. - azithromycin anhydrous (unii: j2klz20u1m) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. community-acquired pneumonia due to chlamydia pneumoniae, haemophilus influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such

AZITHROMYCIN DIHYDRATE- azithromycin tablet, film coated United States - English - NLM (National Library of Medicine)

azithromycin dihydrate- azithromycin tablet, film coated

cardinal health - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, usp are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness

AZITHROMYCIN- azithromycin monohydrate powder, for suspension United States - English - NLM (National Library of Medicine)

azithromycin- azithromycin monohydrate powder, for suspension

preferred pharmaceuticals, inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 100 mg in 5 ml - azithromycin is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration (2) ]. [see use in specific populations (8.4) and clinical studies (14.2) .] azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: to reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacteria

AZITHROMYCIN- azithromycin monohydrate injection, powder, lyophilized, for solution United States - English - NLM (National Library of Medicine)

azithromycin- azithromycin monohydrate injection, powder, lyophilized, for solution

cardinal health - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 500 mg in 5 ml - azithromycin for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below.  as recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see dosage and administration for dosing recommendations. community-acquired pneumonia due to chlamydia pneumoniae, haemophilus influenzae, legionella pneumophila, moraxella catarrhalis, mycoplasma pneumoniae, staphylococcus aureus, or streptococcus pneumoniae in patients who require initial intravenous therapy. pelvic inflammatory disease due to chlamydia trachomatis, neisseria gonorrhoeae, or mycoplasma hominis in patients who require initial intravenous therapy.  if anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with azithromycin for injection, usp. azithromycin for injection, usp should be

AZITHROMYCIN DIHYDRATE- azithromycin tablet, film coated United States - English - NLM (National Library of Medicine)

azithromycin dihydrate- azithromycin tablet, film coated

proficient rx lp - azithromycin dihydrate (unii: 5fd1131i7s) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 250 mg - azithromycin tablets, usp are indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness

AZITHROMYCIN powder, for suspension United States - English - NLM (National Library of Medicine)

azithromycin powder, for suspension

proficient rx lp - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 200 mg in 5 ml - azithromycin for oral suspension usp is indicated for the treatment of patients with mild to moderate infections (pneumonia: see warnings ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. as recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see dosage and administration for specific dosing recommendations. acute bacterial exacerbations of chronic obstructive pulmonary disease due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae. acute bacterial sinusitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae . community-acquired pneumonia due to chlamydophila pneumoniae, haemophilus influenzae, mycoplasma pneumoniae or streptococcus pneumoniae in patients appropriate for oral therapy. note: azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe il

AZITHROMYCIN- azithromycin tablet, film coated United States - English - NLM (National Library of Medicine)

azithromycin- azithromycin tablet, film coated

nucare pharmaceuticals, inc. - azithromycin monohydrate (unii: jte4mnn1md) (azithromycin anhydrous - unii:j2klz20u1m) - azithromycin anhydrous 500 mg - azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see dosage and administration ( 2)]. - acute bacterial exacerbations of chronic bronchitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - acute bacterial sinusitis due to haemophilus influenzae , moraxella catarrhalis, or streptococcus pneumoniae . - community-acquired pneumonia due to chlamydophila pneumoniae , haemophilus influenzae , mycoplasma pneumoniae, or streptococcus pneumoniae in patients appropriate for oral therapy. - pharyngitis/tonsillitis caused by streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. - uncomplicated skin and skin structure infections